Sodium Potassium Chloride Symporter Inhibitors
"Sodium Potassium Chloride Symporter Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that inhibit SODIUM-POTASSIUM-CHLORIDE SYMPORTERS which are concentrated in the thick ascending limb at the junction of the LOOP OF HENLE and KIDNEY TUBULES, DISTAL. They act as DIURETICS. Excess use is associated with HYPOKALEMIA and HYPERGLYCEMIA.
Concept/Terms
Sodium Potassium Chloride Symporter Inhibitors- Sodium Potassium Chloride Symporter Inhibitors
- Na-K-CL Symporter Inhibitors
- Inhibitors, Na-K-CL Symporter
- Na K CL Symporter Inhibitors
- Symporter Inhibitors, Na-K-CL
- Sodium Potassium Chloride Cotransporter Inhibitors
- Bumetanide Sensitive Na-K-Cl-Transporter Inhibitors
- Bumetanide Sensitive Na K Cl Transporter Inhibitors
Below are MeSH descriptors whose meaning is more general than "Sodium Potassium Chloride Symporter Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Sodium Potassium Chloride Symporter Inhibitors".
This graph shows the total number of publications written about "Sodium Potassium Chloride Symporter Inhibitors" by people in Harvard Catalyst Profiles by year, and whether "Sodium Potassium Chloride Symporter Inhibitors" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 1 | 3 | 4 |
| 2009 | 3 | 3 | 6 |
| 2010 | 1 | 4 | 5 |
| 2011 | 2 | 1 | 3 |
| 2012 | 2 | 4 | 6 |
| 2013 | 1 | 2 | 3 |
| 2014 | 2 | 1 | 3 |
| 2015 | 4 | 2 | 6 |
| 2016 | 3 | 2 | 5 |
| 2017 | 2 | 0 | 2 |
| 2018 | 5 | 1 | 6 |
| 2019 | 4 | 3 | 7 |
| 2020 | 1 | 2 | 3 |
| 2021 | 1 | 1 | 2 |
| 2022 | 0 | 5 | 5 |
| 2023 | 0 | 4 | 4 |
Below are the most recent publications written about "Sodium Potassium Chloride Symporter Inhibitors" by people in Profiles.
-
Natriuresis-guided diuretic therapy in acute heart failure: a pragmatic randomized trial. Nat Med. 2023 10; 29(10):2625-2632.
-
Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial. Eur Heart J. 2023 08 14; 44(31):2930-2943.
-
Dapagliflozin vs. metolazone in heart failure resistant to loop diuretics. Eur Heart J. 2023 08 14; 44(31):2966-2977.
-
Cardiovascular and renal effects of SGLT2 inhibitor initiation in acute heart failure: a meta-analysis of randomized controlled trials. Clin Res Cardiol. 2023 Aug; 112(8):1044-1055.
-
Sacubitril/valsartan and loop diuretic requirement in heart failure with preserved ejection fraction in the PARAGON-HF trial. Eur J Heart Fail. 2023 01; 25(1):87-94.
-
Random admission urinary sodium for diuretic response: promise in pragmatism? Eur J Heart Fail. 2022 Oct; 24(10):1988-1989.
-
Association of diuretic use with increased risk for long-term post-transplantation diabetes mellitus in kidney transplant recipients. Nephrol Dial Transplant. 2022 06 23; 37(7):1375-1383.
-
Clarifications regarding bumetanide for neonatal seizures. Epilepsia. 2022 07; 63(7):1863-1867.
-
Natriuresis-guided therapy in acute heart failure: rationale and design of the Pragmatic Urinary Sodium-based treatment algoritHm in Acute Heart Failure (PUSH-AHF) trial. Eur J Heart Fail. 2022 02; 24(2):385-392.
-
Beta-Blocker Use in Hypertension and Heart Failure (A Secondary Analysis of the Systolic Blood Pressure Intervention Trial). Am J Cardiol. 2022 02 15; 165:58-64.